Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Toomey, Paul ^a,b   Kodumudi, Krithika ^a   Weber, Amy ^a   Kuhn, Lisa ^a   Moore, Ellen ^a   Sarnaik, Amod A ^a,b   Pilon Thomas, Shari ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PV 10; ROSE BENGAL; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BREAST CANCER; CANCER CELL CULTURE; CANCER REGRESSION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; LUNG METASTASIS; MELANOMA B16; MOUSE; NONHUMAN; SPLEEN CELL; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INJECTIONS, INTRALESIONAL; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; ROSE BENGAL;

EID: 84880437254     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068561     Document Type: Article

References (28)

1. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, et al. (2000) Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 89: 2646-2654.
2. Guo J, Zhu J, Sheng X, Wang X, Qu L, et al. (2007) Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int J Cancer 120: 2418-2425.
3. Kidner TB, Morton DL, Lee DJ, Hoban M, Foshag LJ, et al. (2012) Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 35: 716-720.
4. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, et al. (2008) Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 31: 520-527.
5. Pilon-Thomas S, Li W, Briggs JJ, Djeu J, Mule JJ, et al. (2006) Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J Immunother 29: 381-387.
6. Boyd KU, Wehrli BM, Temple CL, (2011) Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol 104: 711-717.
7. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, et al. (2010) Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17: 718-730.
8. Machado LM, Castro RS, Fontes BM, (2009) Staining patterns in dry eye syndrome: rose bengal versus lissamine green. Cornea 28: 732-734.
9. Norn MS, (1970) Rose bengal vital staining. Staining of cornea and conjunctiva by 10 prcent rose bengal, compared with 1 percent. Acta Ophthalmol (Copenh) 48: 546-559.
10. Thompson JF, Hersey P, Wachter E, (2008) Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 18: 405-411.
11. Mousavi H, Zhang X, Gillespie S, Wachter E, Hersey P (2006) Rose bengal induces dual modes of cell death in melanoma cells and has clinical activity against melanoma. Melanoma Res 2006.
12. Foote MC, Burmeister BH, Thomas J, Mark Smithers B, (2010) A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series. Melanoma Res 20: 48-51.
13. Pilon-Thomas S, Mackay A, Vohra N, Mule JJ, (2010) Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 184: 3442-3449.
14. Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, et al. (2010) High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 116: 4139-4146.
15. Mastrangelo MJ, Sulit HL, Prehn LM, Bornstein RS, Yarbro JW, et al. (1976) Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer 37: 684-692.
16. Rosenberg SA, Rapp HJ, (1976) Intralesional immunotherapy of melanoma with BCG. Med Clin North Am 60: 419-430.
17. Sopkova B, Kolar V, (1976) Intralesional BCG application in malignant melanoma. Neoplasma 23: 421-426.
18. Bornstein RS, Mastrangelo MJ, Sulit H, Chee D, Yarbro JW, et al. (1973) Immunotherapy of melanoma with intralesional BCG. Natl Cancer Inst Monogr 39: 213-220.
19. Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, et al. (1974) BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180: 635-643.
20. Harper JR, (1982) Anaphylactic reaction to BCG vaccination. Lancet 1: 403-404.
21. Cohen MH, Elin RJ, Cohen BJ, (1991) Hypotension and disseminated intravascular coagulation following intralesional bacillus Calmette-Guerin therapy for locally metastatic melanoma. Cancer Immunol Immunother 32: 315-324.
22. McKhann CF, Hendrickson CG, Spitler LE, Gunnarsson A, Banerjee D, et al. (1975) Immunotherapy of melanoma with BCG: two fatalities following intralesional injection. Cancer 35: 514-520.
23. Robinson JC, (1977) Risks of BCG intralesional therapy: an experience with melanoma. J Surg Oncol 9: 587-593.
24. Felix EL, Jessup JM, Cohen MH, (1978) Severe complications of intralesional BCG therapy in an unsensitized patient. Case report and clinical implications. Arch Surg 113: 893-896.
25. Portelance VQ, M.; Page, (1976) Y (1976) Toxic effects of massive doses of BCG in mice, guinea pigs, and monkeys. Cancer Immunol Immunother 1: 63-67.
26. den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, et al. (2004) In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 64: 4024-4029.
27. Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, et al. (2012) Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 35: 615-620.
28. Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S, (2012) Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 189: 5147-5154.